Content about Pharmacology

February 25, 2014

DSN recently caught up with Dick Domann, VP pharmacy services for TrialCard, to talk about adherence and abandonment solutions. Capturing otherwise lost scripts is a significant opportunity for retail pharmacy, and TrialCard has a tool to help reclaim those prescriptions.

Audio Q&A: DSN recently caught up with Dick Domann, VP pharmacy services for TrialCard, to talk about adherence and abandonment solutions. Capturing otherwise lost scripts is a significant opportunity for retail pharmacy, and TrialCard has a tool to help reclaim those prescriptions. 

February 12, 2014

"You may have heard the good news: through proactive involvement from pharmacists all across the state, California recently passed a law (SB 493 in October, 2013) declaring that pharmacists are healthcare providers who have the authority to provide healthcare services within the state. The law creates a new category of pharmacists by statute, for those who meet the criteria, and as a result creates new opportunities for pharmacists to engage with others more traditionally understood as healthcare providers to assist patients in managing chronic conditions," writes Nathan Ludvigson, director, government business development at Emdeon.

You may have heard the good news: through proactive involvement from pharmacists all across the state, California recently passed a law (SB 493 in October, 2013) declaring that pharmacists are healthcare providers who have the authority to provide healthcare services within the state.

February 7, 2014

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity.
A recent paper from the Centers for Medicare and Medicaid Services delves into these issues and more.

As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity. 

A recent paper from the Centers for Medicare and Medicaid Services delves into these issues and more.

Click here to read the full Generics Drug Report 2014. 

 

November 11, 2013

In terms of boosting medication adherence and prescription volumes, the benefits of consolidating all of a patient’s prescriptions into a single, once-a-month refill process are even greater than previously thought.

In terms of boosting medication adherence and prescription volumes, the benefits of consolidating all of a patient’s prescriptions into a single, once-a-month refill process are even greater than previously thought.

 

August 27, 2013

How can retail pharmacy play a greater role in battling the nation's prescription drug abuse epidemic? Data. To shed light on how CVS Caremark tapped its extensive prescribing database to identify signs of potential inappropriate prescribing, CVS Caremark¹s Troy Brennan talked with DSN about the program and the ongoing efforts to combat prescription drug abuse.

AUDIO Q&A: How can retail pharmacy play a greater role in battling the nation's prescription drug abuse epidemic? Data. To shed light on how CVS Caremark tapped its extensive prescribing database to identify signs of potential inappropriate prescribing, CVS Caremark's Troy Brennan talked with DSN about the program and the ongoing efforts to combat prescription drug abuse.

August 20, 2013

A pair of pharmacists from Whitsett, N.C., were the winners of a special text-to-vote competition to highlight independent pharmacy best practices at the Cardinal Health 2013 Retail Business Conference.

SEATTLE — A pair of pharmacists from Whitsett, N.C., were the winners of a special text-to-vote competition to highlight independent pharmacy best practices at the Cardinal Health 2013 Retail Business Conference. Kasey Woods and Amy Brian of Midtown Pharmacy were chosen from among three finalists who were highlighted in videos presented at the conference in Seattle at the Washington State Convention Center, during the Aug. 9 morning general session.

August 5, 2013

Rob Hooper, national sales manager for OTC with Actavis Pharmaceutical, sat down with DSN to discuss how Actavis is preparing for the inaugural NACDS Total Store Expo. Actavis Pharmaceutical, one of the leaders in the OTC private label industry and recently acquired by Watson Pharmaceutical, plans to leverage its extensive experience within the prescription medicine business to offer best-in-class options across store brand products.

Audio Q&A: Actavis Pharmaceutical, one of the leaders in the OTC private label industry and recently acquired by Watson Pharmaceutical, plans to leverage its extensive experience within the prescription medicine business to offer best-in-class options across store brand products. DSN sat down with Rob Hooper, national sales manager for OTC, to discuss how Actavis is preparing for the inaugural NACDS Total Store Expo.

July 10, 2013

DSN had the opportunity to speak with Christian Tadrus, who has been the pharmacist at Sam’s Health Mart in the Colombia, Mo. area, since 1997. Tadrus, a member of McKesson’s Sponsored Clinical Services pharmacy network, participates in a number of adherence support programs, including the award-winning Pharmacy Intervention adherence coaching program, StudyLink patient recruitment for clinical trials program, and the RxRapid Response pharmacist survey program.

DSN had the opportunity to speak with Christian Tadrus, who has been the pharmacist at Sam’s Health Mart in the Colombia, Mo. area, since 1997.

June 25, 2013

The healthcare industry continues to prepare for ACA implementation and the expected influx of newly eligible patients, said Emdeon's Kevin Mahoney. Many pharmacies are changing their staffing models in preparation for customers with expanded Medicaid benefits — especially as we approach the New Year. This is a good time for me to remind you to be thinking about your eligibility program.

In January, I offered Drug Store News readers a look at the pharmacy and technology trends facing our industry for the year. Here we are in June (can you believe it?), so I thought we should have a progress check and update for the back half of 2013.

May 6, 2013

There is no substitute for the face-to-face counsel of the pharmacist in improving patient adherence — and he’s got the data to prove it. That’s the message Thrifty White president and CEO Bob Narveson had for DSNTV in part two of a frank and broad-ranging interview about the state of the industry, the role community pharmacy can play in healthcare reform and the results of an exciting new study that validates the role companies like his can play to innovate patient care, improve outcomes and lower healthcare costs.

FARGO, N.D. — There is no substitute for the face-to-face counsel of the pharmacist in improving patient adherence — and he’s got the data to prove it. That’s the message Thrifty White president and CEO Bob Narveson had for DSNTV in part two of a frank and broad-ranging interview about the state of the industry, the role community pharmacy can play in healthcare reform and the results of an exciting new study that validates the role companies like his can play to innovate patient care, improve outcomes and lower healthcare costs.

April 12, 2013

Westport VP and general manager Paul Hemings spoke with DSN about the company's introduction of Zephrex-D, a meth-resistant pseudoephedrine product, to market. Beyond taking a bite out of the $23.5 billion methamphetamine trade, Hemings discussed the benefits of having Zephrex-D behind the pharmacy counter.

AUDIO Q&A: Westport VP and general manager Paul Hemings spoke with DSN about the company's introduction of Zephrex-D, a meth-resistant pseudoephedrine product, to market. Beyond taking a bite out of the $23.5 billion methamphetamine trade, Hemings discussed the benefits of having Zephrex-D behind the pharmacy counter.

April 2, 2013

DSN caught up with Greg Bradley — president and CEO of Advantage Consumer Healthcare, a full turnkey solution center for over-the-counter medicines reaching the market — for an overview of the new marketing and sales solution company as it has recently brought to market OraSure Technologies' OraQuick Advance, a take-home HIV test kit that the Food and Drug Administration recently approved for the self-care market, and Westport Pharmaceuticals' Zephrex-D, a pseudoephedrine product with a unique point of differentiation.

AUDIO Q&A: DSN caught up with Greg Bradley — president and CEO of Advantage Consumer Healthcare, a full turnkey solution center for over-the-counter medicines reaching the market — for an overview of the new marketing and sales solution company as it has recently brought to market OraSure Technologies' OraQuick Advance, a take-home HIV test kit that the Food and Drug Administration recently approved for the self

December 10, 2012

DSN looks back on the past year's most influential events in the pharmacy industry, from Obamacare and record patent expirations to Humira surpassing Lipitor as the world's top-selling drug and the merger of Walgreens and Alliance Boots.

DSN looks back on the past year's most influential events in the pharmacy industry, from Obamacare and record patent expirations to Humira surpassing Lipitor as the world's top-selling drug and the merger of Walgreens and Alliance Boots.

 

November 19, 2012

The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.

The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.

 

September 18, 2012

In part two, DSN asks pharmacists to name their top OTC brand recommendations across 15 core product categories.

Part one of the first annual Drug Store News pharmacist-reader survey revealed how quickly the practice of pharmacy is evolving to have a greater emphasis on patient care. Nearly half (46%) indicated they had been spending more time counseling patients in recent years, and slightly more (50.5%) said their pharmacies were doing more work around disease state management and chronic care programs.

In all, 378 pharmacists completed the survey, which was conducted between July 31 and Aug. 6.

July 11, 2012

DSN talked to Cardinal Health SVP independent sales Steve Lawrence about the big news from Cardinal’s 2012 Retail Business Conference, including a best practices competition for its customers, its Women in Pharmacy program and Cardinal’s joint outreach program with the Ohio State University College of Pharmacy aimed at preventing prescription drug abuse.

AUDIO Q&A: DSN talked to Cardinal Health SVP independent sales Steve Lawrence about the big news from Cardinal’s 2012 Retail Business Conference, including a best practices competition for its customers, its Women in Pharmacy program and Cardinal’s joint outreach program with the Ohio State University College of Pharmacy aimed at preventing prescription drug abuse.

August 24, 2011

Behind every prescription that lands at the pharmacy counter is a series of events that influence the prescriber’s decision. Powered by data from SDI Health, Drug Store News goes inside the examination room in this exclusive report, providing an in-depth look at the critical factors that shape pharmaceutical sales trends and shift market share from one drug to another in 10 key market segments.

Behind every prescription that lands at the pharmacy counter is a series of events that influence the prescriber’s decision. Powered by data from SDI Health, Drug Store News goes inside the examination room in this exclusive report, providing an in-depth look at the critical factors that shape pharmaceutical sales trends and shift market share from one drug to another in 10 key market segments.

Click below to download the complete PDF of the 2011 Annual Prescriber Report.

April 15, 2014

Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products.

PEAPACK, N.J. — Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products. The drug is the authorized generic versions of Caduet.

April 15, 2014

Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services overall rose for the first time in three years, according to a new report issued today by the IMS Institute for Healthcare Informatics.

PARSIPPANY, N.J. — Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services overall rose for the first time in three years, according to a new report issued today by the IMS Institute for Healthcare Informatics.

April 15, 2014

Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use.

WHITEHOUSE STATION, N.J. — Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use. The drug is an allergen extract used for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. It is approved for use in persons ages 5 years through 65 years of age.

April 15, 2014

Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.

OXFORD, England  — Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by Design, on Tuesday announced that it has entered into a global licensing agreement with Mylan for its leading inhaled respiratory products, PSX1001 and PSX1050.

April 15, 2014

Quest Products on Friday announced the addition of a gel formulated for emergency burn relief, Alocane Emergency Burn Gel, to its current line of products.

GURNEE, Ill. — Quest Products on Friday announced the addition of a gel formulated for emergency burn relief, Alocane Emergency Burn Gel, to its current line of products. Previously a top-selling product on retail shelves in the 80's and 90's, it was taken off the market due to financial difficulties facing the parent company, First Pharmaceutical.

April 15, 2014

The Food and Drug Administration on Tuesday announced that it approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced that it has approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.

Type 2 diabetes affects approximately 24 million people and accounts for more than 90% of diabetes cases diagnosed in the United States.

April 15, 2014

Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States.

JERUSALEM — Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States. The drug is used to treat insomnia.

Lunesta tablets, which are marketed by Sunovion Pharmaceuticals, had annual sales of $852 million in the United States as of December 2013, according to IMS data.

 

April 14, 2014

AssistRx last week introduced a new technology that simplifies the prescribing of specialty therapies while streamlining communications between prescribers, pharmacies, patients and manufacturers. It’s smart technology that can lead to patients receiving specialty medications weeks earlier than ever before, the company claimed.

ORLANDO, Fla. — AssistRx last week introduced a new technology that simplifies the prescribing of specialty therapies while streamlining communications between prescribers, pharmacies, patients and manufacturers. It’s smart technology that can lead to patients receiving specialty medications weeks earlier than ever before, the company claimed.